LUPUS ANTICOAGULANT AND SEVERE PRE-ECLAMPSIA OR ECLAMPSIA: A HOSPITAL-BASED CASE-CONTROL STUDY IN OUAGADOUGOU, BURKINA FASO,
Lien de l'article: DOI: 10.35503/IJMLR.2021.6301
Auteur(s): SAWADOGO Salam1,2, MINOUNGOU née OUATTARA Aminata3, NEBIE Koumpingnin1,2, NIKIEMA née MINOUNGOU Myriam4, SANOU Aboubacar5, MILLOGO Tieba6, KAFANDO Eléonore1,7
Auteur(s) tagués: Salam SAWADOGO ;
Résumé

Background: Antiphospholipid antibodies are recognized to be associated to thrombosis and
obstetric complications. Preeclampsia is a frequent pregnancy complication in our context. The objective of our
study was to determine the prevalence of lupus anticoagulant (LA) and its association with severe pre-eclampsia
and eclampsia in Burkina Faso. Methods: We carried out a hospital-based unmatched case-control study
including 86 women with severe preeclampsia or eclampsia and 87 controls. LA were diagnosed using Diluted
Russel's Viper Venom time screening and confirmation tests. Positive lupus anticoagulant was defined if the
screen to confirmation ratio was over 1.2. Results: The prevalence of LA was 22.1% in women with
preeclampsia or eclampsia and 3.4% in control (OR = 6.12; 1.45 – 25.84; p = 0.014). The primigravida
accounted for68.2% of positive LA and had 2.69 odds of being positive to lupus anticoagulant compared to
multigravida (OR = 2.69; [1.04 – 6.97]; p = 0.042). The LA could be suspected to be a part of the aetiologies of
obstetrical complications (cases of obstetric antiphospholipid syndrome) in four cases (4.6%) of study-group.
Conclusion: We certainly failed to diagnosis all cases of obstetric antiphospholipid syndrome in our study
population, since we screened only LA. It is necessary to implement complementary assays for antiphospholipid
antibodies detection in order to improve the exploration of pregnancy complications and thrombotic diseases.

Mots-clés

962
Enseignants
5577
Publications
49
Laboratoires
84
Projets